Sample Request

2020-2025 Global Epidermolysis Bullosa (EB) Therapeutics Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)

SELECT LICENSE:

Published on 03/09/2021| Code: MAR41115D| Category: Healthcare & Life Sciences| Total Pages: 108

Epidermolysis Bullosa (EB) is a category of rare genetic disorders involving the skin and skin-like tissues. EB is generally inherited from one or both parents who have been diagnosed with EB or carry as mutated EB gene. Rarely, EB can also occur in an individual due to a new genetic mutation, which might have been absent in either or both parents. People suffering from EB have fragile skin which causes blisters that can lead to wounds which are difficult to heal. Low prevalence, lack of data, and no available medications make EB a non-curable disease. A Severe form of EB can be a cause of cancer. At present EB is categorized into EB simplex, Junctional EB, Dystrophic EB, and Kindler Syndrome.

This report elaborates the market size, market characteristics, and market growth of the Epidermolysis Bullosa (EB) Therapeutics industry, and breaks down according to the type, application, and consumption area of Epidermolysis Bullosa (EB) Therapeutics. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Epidermolysis Bullosa (EB) Therapeutics in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.

In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.

Key players in the global Epidermolysis Bullosa (EB) Therapeutics market covered in Chapter 13:

InMed Pharmaceuticals Inc.
Pfizer
Karus Therapeutics Limited
Fibrocell Science, Inc.
GlaxoSmithKline Plc.
Amryt Pharma
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Amicus Therapeutics
Scioderm, Inc.
TWi Pharmaceuticals, Inc.
Johnson & Johnson
Birken AG
RegeneRx Biopharma
InMed Pharmaceuticals Inc
Novartis
Fresenius

In Chapter 6, on the basis of types, the Epidermolysis Bullosa (EB) Therapeutics market from 2015 to 2025 is primarily split into:

Epidermolysis Bullosa Care
Pharmacological Drugs
Surgical Treatment
Pipeline Therapies

In Chapter 7, on the basis of applications, the Epidermolysis Bullosa (EB) Therapeutics market from 2015 to 2025 covers:

Application 1

Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:

United States

Europe

China

Japan

India

Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:

North America (Covered in Chapter 8)

United States

Canada

Mexico

Europe (Covered in Chapter 9)

Germany

UK

France

Italy

Spain

Others

Asia-Pacific (Covered in Chapter 10)

China

Japan

India

South Korea

Southeast Asia

Others

Middle East and Africa (Covered in Chapter 11)

Saudi Arabia

UAE

South Africa

Others

South America (Covered in Chapter 12)

Brazil

Others

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

Table of Content

1 Epidermolysis Bullosa (EB) Therapeutics Market - Research Scope

1.1 Study Goals

1.2 Market Definition and Scope

1.3 Key Market Segments

1.4 Study and Forecasting Years

2 Epidermolysis Bullosa (EB) Therapeutics Market - Research Methodology

2.1 Methodology

2.2 Research Data Source

2.2.1 Secondary Data

2.2.2 Primary Data

2.2.3 Market Size Estimation

2.2.4 Legal Disclaimer

3 Epidermolysis Bullosa (EB) Therapeutics Market Forces

3.1 Global Epidermolysis Bullosa (EB) Therapeutics Market Size

3.2 Top Impacting Factors (PESTEL Analysis)

3.2.1 Political Factors

3.2.2 Economic Factors

3.2.3 Social Factors

3.2.4 Technological Factors

3.2.5 Environmental Factors

3.2.6 Legal Factors

3.3 Industry Trend Analysis

3.4 Industry Trends Under COVID-19

3.4.1 Risk Assessment on COVID-19

3.4.2 Assessment of the Overall Impact of COVID-19 on the Industry

3.4.3 Pre COVID-19 and Post COVID-19 Market Scenario

3.5 Industry Risk Assessment

4 Epidermolysis Bullosa (EB) Therapeutics Market - By Geography

4.1 Global Epidermolysis Bullosa (EB) Therapeutics Market Value and Market Share by Regions

4.1.1 Global Epidermolysis Bullosa (EB) Therapeutics Value ($) by Region (2015-2020)

4.1.2 Global Epidermolysis Bullosa (EB) Therapeutics Value Market Share by Regions (2015-2020)

4.2 Global Epidermolysis Bullosa (EB) Therapeutics Market Production and Market Share by Major Countries

4.2.1 Global Epidermolysis Bullosa (EB) Therapeutics Production by Major Countries (2015-2020)

4.2.2 Global Epidermolysis Bullosa (EB) Therapeutics Production Market Share by Major Countries (2015-2020)

4.3 Global Epidermolysis Bullosa (EB) Therapeutics Market Consumption and Market Share by Regions

4.3.1 Global Epidermolysis Bullosa (EB) Therapeutics Consumption by Regions (2015-2020)

4.3.2 Global Epidermolysis Bullosa (EB) Therapeutics Consumption Market Share by Regions (2015-2020)

5 Epidermolysis Bullosa (EB) Therapeutics Market - By Trade Statistics

5.1 Global Epidermolysis Bullosa (EB) Therapeutics Export and Import

5.2 United States Epidermolysis Bullosa (EB) Therapeutics Export and Import (2015-2020)

5.3 Europe Epidermolysis Bullosa (EB) Therapeutics Export and Import (2015-2020)

5.4 China Epidermolysis Bullosa (EB) Therapeutics Export and Import (2015-2020)

5.5 Japan Epidermolysis Bullosa (EB) Therapeutics Export and Import (2015-2020)

5.6 India Epidermolysis Bullosa (EB) Therapeutics Export and Import (2015-2020)

5.7 ...

6 Epidermolysis Bullosa (EB) Therapeutics Market - By Type

6.1 Global Epidermolysis Bullosa (EB) Therapeutics Production and Market Share by Types (2015-2020)

6.1.1 Global Epidermolysis Bullosa (EB) Therapeutics Production by Types (2015-2020)

6.1.2 Global Epidermolysis Bullosa (EB) Therapeutics Production Market Share by Types (2015-2020)

6.2 Global Epidermolysis Bullosa (EB) Therapeutics Value and Market Share by Types (2015-2020)

6.2.1 Global Epidermolysis Bullosa (EB) Therapeutics Value by Types (2015-2020)

6.2.2 Global Epidermolysis Bullosa (EB) Therapeutics Value Market Share by Types (2015-2020)

6.3 Global Epidermolysis Bullosa (EB) Therapeutics Production, Price and Growth Rate of Epidermolysis Bullosa Care (2015-2020)
6.4 Global Epidermolysis Bullosa (EB) Therapeutics Production, Price and Growth Rate of Pharmacological Drugs (2015-2020)
6.5 Global Epidermolysis Bullosa (EB) Therapeutics Production, Price and Growth Rate of Surgical Treatment (2015-2020)
6.6 Global Epidermolysis Bullosa (EB) Therapeutics Production, Price and Growth Rate of Pipeline Therapies (2015-2020)

7 Epidermolysis Bullosa (EB) Therapeutics Market - By Application

7.1 Global Epidermolysis Bullosa (EB) Therapeutics Consumption and Market Share by Applications (2015-2020)

7.1.1 Global Epidermolysis Bullosa (EB) Therapeutics Consumption by Applications (2015-2020)

7.1.2 Global Epidermolysis Bullosa (EB) Therapeutics Consumption Market Share by Applications (2015-2020)

7.2 Global Epidermolysis Bullosa (EB) Therapeutics Consumption and Growth Rate of Application 1 (2015-2020)

8 North America Epidermolysis Bullosa (EB) Therapeutics Market

8.1 North America Epidermolysis Bullosa (EB) Therapeutics Market Size

8.2 United States Epidermolysis Bullosa (EB) Therapeutics Market Size

8.3 Canada Epidermolysis Bullosa (EB) Therapeutics Market Size

8.4 Mexico Epidermolysis Bullosa (EB) Therapeutics Market Size

8.5 The Influence of COVID-19 on North America Market

9 Europe Epidermolysis Bullosa (EB) Therapeutics Market Analysis

9.1 Europe Epidermolysis Bullosa (EB) Therapeutics Market Size

9.2 Germany Epidermolysis Bullosa (EB) Therapeutics Market Size

9.3 United Kingdom Epidermolysis Bullosa (EB) Therapeutics Market Size

9.4 France Epidermolysis Bullosa (EB) Therapeutics Market Size

9.5 Italy Epidermolysis Bullosa (EB) Therapeutics Market Size

9.6 Spain Epidermolysis Bullosa (EB) Therapeutics Market Size

9.7 The Influence of COVID-19 on Europe Market

10 Asia-Pacific Epidermolysis Bullosa (EB) Therapeutics Market Analysis

10.1 Asia-Pacific Epidermolysis Bullosa (EB) Therapeutics Market Size

10.2 China Epidermolysis Bullosa (EB) Therapeutics Market Size

10.3 Japan Epidermolysis Bullosa (EB) Therapeutics Market Size

10.4 South Korea Epidermolysis Bullosa (EB) Therapeutics Market Size

10.5 Southeast Asia Epidermolysis Bullosa (EB) Therapeutics Market Size

10.6 India Epidermolysis Bullosa (EB) Therapeutics Market Size

10.7 The Influence of COVID-19 on Asia Pacific Market

11 Middle East and Africa Epidermolysis Bullosa (EB) Therapeutics Market Analysis

11.1 Middle East and Africa Epidermolysis Bullosa (EB) Therapeutics Market Size

11.2 Saudi Arabia Epidermolysis Bullosa (EB) Therapeutics Market Size

11.3 UAE Epidermolysis Bullosa (EB) Therapeutics Market Size

11.4 South Africa Epidermolysis Bullosa (EB) Therapeutics Market Size

11.5 The Influence of COVID-19 on Middle East and Africa Market

12 South America Epidermolysis Bullosa (EB) Therapeutics Market Analysis

12.1 South America Epidermolysis Bullosa (EB) Therapeutics Market Size

12.2 Brazil Epidermolysis Bullosa (EB) Therapeutics Market Size

12.3 The Influence of COVID-19 on South America Market

13 Company Profiles

13.1 InMed Pharmaceuticals Inc.
13.1.1 InMed Pharmaceuticals Inc. Basic Information
13.1.2 InMed Pharmaceuticals Inc. Product Profiles, Application and Specification
13.1.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.2 Pfizer
13.2.1 Pfizer Basic Information
13.2.2 Pfizer Product Profiles, Application and Specification
13.2.3 Pfizer Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.3 Karus Therapeutics Limited
13.3.1 Karus Therapeutics Limited Basic Information
13.3.2 Karus Therapeutics Limited Product Profiles, Application and Specification
13.3.3 Karus Therapeutics Limited Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.4 Fibrocell Science, Inc.
13.4.1 Fibrocell Science, Inc. Basic Information
13.4.2 Fibrocell Science, Inc. Product Profiles, Application and Specification
13.4.3 Fibrocell Science, Inc. Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.5 GlaxoSmithKline Plc.
13.5.1 GlaxoSmithKline Plc. Basic Information
13.5.2 GlaxoSmithKline Plc. Product Profiles, Application and Specification
13.5.3 GlaxoSmithKline Plc. Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.6 Amryt Pharma
13.6.1 Amryt Pharma Basic Information
13.6.2 Amryt Pharma Product Profiles, Application and Specification
13.6.3 Amryt Pharma Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.7 ProQR Therapeutics N.V.
13.7.1 ProQR Therapeutics N.V. Basic Information
13.7.2 ProQR Therapeutics N.V. Product Profiles, Application and Specification
13.7.3 ProQR Therapeutics N.V. Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.8 RegeneRx Biopharmaceuticals, Inc.
13.8.1 RegeneRx Biopharmaceuticals, Inc. Basic Information
13.8.2 RegeneRx Biopharmaceuticals, Inc. Product Profiles, Application and Specification
13.8.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.9 Amicus Therapeutics
13.9.1 Amicus Therapeutics Basic Information
13.9.2 Amicus Therapeutics Product Profiles, Application and Specification
13.9.3 Amicus Therapeutics Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.10 Scioderm, Inc.
13.10.1 Scioderm, Inc. Basic Information
13.10.2 Scioderm, Inc. Product Profiles, Application and Specification
13.10.3 Scioderm, Inc. Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.11 TWi Pharmaceuticals, Inc.
13.11.1 TWi Pharmaceuticals, Inc. Basic Information
13.11.2 TWi Pharmaceuticals, Inc. Product Profiles, Application and Specification
13.11.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.12 Johnson & Johnson
13.12.1 Johnson & Johnson Basic Information
13.12.2 Johnson & Johnson Product Profiles, Application and Specification
13.12.3 Johnson & Johnson Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.13 Birken AG
13.13.1 Birken AG Basic Information
13.13.2 Birken AG Product Profiles, Application and Specification
13.13.3 Birken AG Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.14 RegeneRx Biopharma
13.14.1 RegeneRx Biopharma Basic Information
13.14.2 RegeneRx Biopharma Product Profiles, Application and Specification
13.14.3 RegeneRx Biopharma Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.15 InMed Pharmaceuticals Inc
13.15.1 InMed Pharmaceuticals Inc Basic Information
13.15.2 InMed Pharmaceuticals Inc Product Profiles, Application and Specification
13.15.3 InMed Pharmaceuticals Inc Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.16 Novartis
13.16.1 Novartis Basic Information
13.16.2 Novartis Product Profiles, Application and Specification
13.16.3 Novartis Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)
13.17 Fresenius
13.17.1 Fresenius Basic Information
13.17.2 Fresenius Product Profiles, Application and Specification
13.17.3 Fresenius Epidermolysis Bullosa (EB) Therapeutics Market Performance (2015-2020)

14 Market Forecast - By Regions

14.1 North America Epidermolysis Bullosa (EB) Therapeutics Market Forecast (2020-2025)

14.2 Europe Epidermolysis Bullosa (EB) Therapeutics Market Forecast (2020-2025)

14.3 Asia-Pacific Epidermolysis Bullosa (EB) Therapeutics Market Forecast (2020-2025)

14.4 Middle East and Africa Epidermolysis Bullosa (EB) Therapeutics Market Forecast (2020-2025)

14.5 South America Epidermolysis Bullosa (EB) Therapeutics Market Forecast (2020-2025)

15 Market Forecast - By Type and Applications

15.1 Global Epidermolysis Bullosa (EB) Therapeutics Market Forecast by Types (2020-2025)

15.1.1 Global Epidermolysis Bullosa (EB) Therapeutics Market Forecast Production and Market Share by Types (2020-2025)

15.1.2 Global Epidermolysis Bullosa (EB) Therapeutics Market Forecast Value and Market Share by Types (2020-2025)

15.2 Global Epidermolysis Bullosa (EB) Therapeutics Market Forecast by Applications (2020-2025)

Our Clients

BIC
Suntory Holdings
Continental AG
Ernst Klett
felix
IF Logo
ITC logo
jc
KB
KKR
LR
LSC
Prospect
SRG
Sumitomo
Taichin logo
The Cleanest Way
Meat & Livestock Australia Limited
LEK
IFFCO
STTS
Laundry Capital LLC
Chippenhook Corporation
SAB
IJIN
Hooton
Medica
Medalliacne
Shanghai Chenzhu Instrument Co., Ltd.
Sanofi
Kleen Linnebo und Partner GbR
Bond-Pro, Inc.
E&L Faster Food Imports Inc.
Okinawa Institute of Science and Technology
Mizuno Corp

Need Help?

Please fill form below:

Contact Us

99 WALL STREET #2124 NEW YORK, NY 10005